Our approach is unique from other targeting technologies such as large antibodies. Our focus on small, high-affinity targeting ligands (300 times smaller than antibodies), facilitates their penetration into dense tumors and rapid clearance from the body reducing the risk of toxicity to normal cells. This approach to targeted drug therapy opens up the potential for safer and more effective treatment approaches using:
high-potency drugs that may not have been developed due to toxicity. Our pipeline includes drugs that are 1,000 – 10,000 times more potent than existing cancer therapies such as cisplatin.
a more effective dose-dense schedule to put constant pressure on the tumor. In early clinical studies, EC145, a targeted super-potent vinca, was dosed daily for 3 consecutive weeks with minimal toxicity.
a new combination of drugs that could not be dosed due to overlapping toxicity. EC0225 targets a combination of two highly potent chemotherapy drugs. Preclinical data showed this drug could cure even very large tumors.
|
